BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30037483)

  • 1. Development of a human papillomavirus type 6/11 vaccine candidate for the prevention of condyloma acuminatum.
    Yu Y; Guo J; Li D; Liu Y; Yu Y; Wang L
    Vaccine; 2018 Aug; 36(32 Pt B):4927-4934. PubMed ID: 30037483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacterially expressed human papillomavirus type 6 and 11 bivalent vaccine: Characterization, antigenicity and immunogenicity.
    Pan H; Li Z; Wang J; Song S; Wang D; Wei M; Gu Y; Zhang J; Li S; Xia N
    Vaccine; 2017 May; 35(24):3222-3231. PubMed ID: 28483196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression, purification and immunogenicity of human papillomavirus type 11 virus-like particles from Escherichia coli].
    Yan C; Li S; Wang J; Wei M; Huang B; Zhuang Y; Li Z; Pan H; Zhang J; Xia N
    Wei Sheng Wu Xue Bao; 2009 Nov; 49(11):1527-33. PubMed ID: 20112683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mixed Bacteriophage MS2-L2 VLPs Elicit Long-Lasting Protective Antibodies against HPV Pseudovirus 51.
    Yadav R; Zhai L; Kunda NK; Muttil P; Tumban E
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34200586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials.
    Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G
    Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cervix carcinoma--Austrian Vaccination Committee recommends HPV vaccination].
    Six L; Joura EA
    Wien Med Wochenschr; 2007; 157(5-6):130-2. PubMed ID: 17427010
    [No Abstract]   [Full Text] [Related]  

  • 9. [Value of general human papillomavirus vaccination in sexually active women].
    Hampl M
    Dtsch Med Wochenschr; 2009 Apr; 134 Suppl 2():S95-9. PubMed ID: 19353480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.
    Joura EA; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch X; Dillner J; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Lu S; Vuocolo S; Hesley TM; Haupt RM; Barr E
    Vaccine; 2008 Dec; 26(52):6844-51. PubMed ID: 18930097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A case for immunization of human papillomavirus (HPV) 6/11-infected pregnant women with the quadrivalent HPV vaccine to prevent juvenile-onset laryngeal papilloma.
    Shah KV
    J Infect Dis; 2014 May; 209(9):1307-9. PubMed ID: 24265442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered antigenicity and immunogenicity of human papillomavirus virus-like particles in the presence of thimerosal.
    Chen S; Huang X; Li Y; Wang X; Pan H; Lin Z; Zheng Q; Li S; Zhang J; Xia N; Zhao Q
    Eur J Pharm Biopharm; 2019 Aug; 141():221-231. PubMed ID: 31154067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
    Woestenberg PJ; King AJ; van der Sande MA; Donken R; Leussink S; van der Klis FR; Hoebe CJ; Bogaards JA; van Benthem BH; ;
    J Infect; 2017 Apr; 74(4):393-400. PubMed ID: 28126492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for the presence of neutralizing antibodies against human papillomavirus type 6 in infants born to mothers with condyloma acuminata.
    Kawana K; Yasugi T; Yoshikawa H; Kawana Y; Matsumoto K; Nakagawa S; Onda T; Kikuchi A; Fujii T; Kanda T; Taketani Y
    Am J Perinatol; 2003 Jan; 20(1):11-6. PubMed ID: 12638076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus L1 protein expressed in Escherichia coli self-assembles into virus-like particles that are highly immunogenic.
    Chen Y; Liu Y; Zhang G; Wang A; Dong Z; Qi Y; Wang J; Zhao B; Li N; Jiang M
    Virus Res; 2016 Jul; 220():97-103. PubMed ID: 27107614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.
    Safaeian M; Porras C; Pan Y; Kreimer A; Schiller JT; Gonzalez P; Lowy DR; Wacholder S; Schiffman M; Rodriguez AC; Herrero R; Kemp T; Shelton G; Quint W; van Doorn LJ; Hildesheim A; Pinto LA;
    Cancer Prev Res (Phila); 2013 Nov; 6(11):1242-50. PubMed ID: 24189371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL; Joura EA
    BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing Chimeric Virus-like Particle-based Vaccines for Human Papillomavirus and HIV: Lessons Learned.
    Eto Y; Saubi N; Ferrer P; Joseph J
    AIDS Rev; 2019; 21(4):218-232. PubMed ID: 31834327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain.
    Ludmerer SW; McClements WL; Wang XM; Ling JC; Jansen KU; Christensen ND
    Virology; 2000 Jan; 266(2):237-45. PubMed ID: 10639310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human papillomavirus typing in reporting of condyloma.
    Sturegård E; Johansson H; Ekström J; Hansson BG; Johnsson A; Gustafsson E; Dillner J; Forslund O
    Sex Transm Dis; 2013 Feb; 40(2):123-9. PubMed ID: 23324975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.